Investing
Cathie Wood's ARK Invest Sells Over 225,000 Shares of Takeda Pharma
Published:
Last Updated:
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) on Tuesday, as the share price of this fund traded down over 2% in the day’s session. The fund’s share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 228,234 shares of Takeda Pharma. At Tuesday’s closing price, this would have valued this sale at roughly $3.9 million. This is only a small fraction of the total holdings. This fund is up 88% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | TCSLI | TCS GROUP HOLDING PLC | 50,650 |
| ARKG | PSTI | PLURISTEM THERAPEUTICS INC | 1,131 |
| ARKG | NVS | NOVARTIS AG | 139,576 |
| ARKG | SRPT | SAREPTA THERAPEUTICS INC | 48,004 |
| ARKG | TAK | TAKEDA PHARMACEUTICAL CO LTD | 228,234 |
| ARKK | ICE | INTERCONTINENTAL EXCHANGE INC | 196,304 |
| ARKQ | TER | TERADYNE INC | 23,160 |
| ARKQ | RAVN | RAVEN INDUSTRIES INC | 32,733 |
| ARKQ | GLEO | GALILEO ACQUISITION CORP | 5,888 |
| ARKW | NET | CLOUDFLARE INC | 72,257 |
| ARKX | AIRFP | AIRBUS SE | 16,050 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
